Clinical Trial of SAHA in Patients With Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00416130|
Recruitment Status : Unknown
Verified December 2013 by Haematology-Oncology, National University Hospital, Singapore.
Recruitment status was: Active, not recruiting
First Posted : December 27, 2006
Last Update Posted : December 10, 2013
National University Hospital, Singapore
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Haematology-Oncology, National University Hospital, Singapore
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||January 2015|
|Estimated Study Completion Date :||January 2015|
Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001 Dec 1;61(23):8492-7.
Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005 Jun 10;23(17):3923-31. Epub 2005 May 16.